Takeda To Purchase IDM Pharma To Boost Oncology Business
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical May 18 announced a buyout plan to acquire U.S. biopharmaceutical company IDM Pharma. Takeda plans to pay $75 million to obtain all outstanding shares of the Nasdaq-listed company. IDM has obtained approval in the EU for Mepact (mifamurtide), the first treatment approved for osteosarcoma. Through the buyout, Takeda plans to market the drug through marketing branches in Europe and expand its oncology business in the European market. (Click here for more - Japanese language
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.